VICTOR L. YU, M.D.
Moxalactam is a new broad-spectrum antimicrobial drug that is structurally related to the cephalosporins (1). Its favorable pharmacokinetic properties allow it to be administered at 8-hour intervals (2), and unlike other cephalosporins, it reaches the cerebrospinal fluid in therapeutic concentrations (3). However, its major attraction is its effectiveness in vitro against many bacterial pathogens. It is active against the usual pathogenic gram-positive cocci (streptococci, pneumococci, staphylococci) as well as the Enterobacteriaceae (1, 4). Moreover, it is active in vitro against anaerobes (including Bacteroides fragilis) as well as Haemophilus influenzae (including ampicillin-resistant strains) and Pseudomonas aeruginosa (4-6). No other commercially available
YU VL. Enterococcal Superinfection and Colonization After Therapy with Moxalactam, a New Broad-Spectrum Antibiotic. Ann Intern Med. ;94:784–785. doi: 10.7326/0003-4819-94-6-784
Download citation file:
Published: Ann Intern Med. 1981;94(6):784-785.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use